Novo Nordisk has announced significant positive results from a Phase 2 trial of its experimental triple agonist, UBT251, reporting a…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly’s investigational drug, retatrutide, a pioneering first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has delivered extraordinary results…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
For decades, successive waves of antidepressants have promised relief to millions suffering from mood disorders, yet the landscape for those…
Read More
Eli Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial, revealing that its investigational triple agonist,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, recently announced compelling Phase 2 trial results for its investigational…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
For decades, the medical community has grappled with the persistent challenge of mood disorders, offering successive waves of antidepressants that,…
Read More
Eli Lilly’s Triple Agonist Retatrutide Achieves Remarkable 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes
Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
The landscape of mental health treatment witnessed a significant development on February 17, 2026, as Compass Pathways, a leading mental…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
